Key Points Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is ...

If you're looking for a top healthcare stock to buy that has much more upside in GLP-1, then going with Eli Lilly or Novo Nordisk can make much more sense at this stage.

Eli Lilly signs another genetic medicines deal, this time with Genetic Leap, a start-up that applies AI to the discovery of RNA-targeted drugs.

Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.

By Deena Beasley (Reuters) -The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the ...

Eli Lilly and Novo Nordisk dominate the weight-loss drug market. But pharma companies like Amgen, Viking, Zealand, Structure, AstraZeneca and Roche are racing to catch up.